Marfan syndrome is one of the more frequent autosomal syndromes. Its frequency has been estimated at 4 to 6 in 100 000 births. Approximately 15 % of the cases are spontaneous mutations.1 There is great variability of the phenotypic manifestations of the disease which may be explained in part by variable penetrance of the gene or genetic heterogeneity.2 As in most autosomal dominant diseases, affected subjects are usually heterozygous for the mutant gene.
We report a family in which the gene for Marfan syndrome is segregating. In this kindred, a large number of persons have different manifestations of the disease. Two sibs are described in detail, with identical uncommonly severe manifestations from birth. These patients raise the possibility of homozygosity for the Marfan syndrome gene. The possibility of an autosomal recessive 'Marfan-like' disease of connective tissue cannot be definitely ruled out at present, since so far no specific abnormal collagen for Marfan syndrome is known.
Family history and case reports
The family pedigree is presented in fig 1 type of autosomal dominant brachydactyly, the Pelger-Huet anomaly of leucocytes, hereditary haemorrhagic telangiectasia, and familial hypercholesterolinaemia.6
One of the difficulties in characterising Marfan syndrome is the absence of a specific demonstrable defect in the biosynthesis of collagen. Lysyl oxidase activity, the enzyme that initiates cross linking, has been reported to be normal in fibroblasts. The collagen in skin fibroblasts of affected subjects is more easily extracted in aqueous and denaturating buffers than collagen in normal controls.8 14ow-ever, the stability of the insoluble fraction is decreased only in growing adolescent patients.10 Furthermore, skin fibroblasts from patients with Marfan syndrome synthesise approximately five times more hyaluronic acid than normal human skin fibroblasts." It has been suggested that this is because of a defect in the control of the synthesis of hyaluronic acid'2 owing to increased activity of the hyaluronic acid synthetase.'3 Several alterations in the biosynthesis of collagenous proteins in patients with Marfan syndrome have been described. These include differences in the proportions of collagen types I and III14 and changes in the ultrastructure and composition of collagen in aortic tissue. However, other possible genetic mechanisms have to be considered, even though none can be proven owing to the lack of a specific detectable abnormality of collagen. Fried and Krakowski19 postulated autosomal recessive inheritance for Marfan syndrome in a family in which there were two affected sisters in a sibship with completely normal and non-consanguineous parents. In the family presented here, the parents are first cousins and both patients had a similar disease. Therefore, it could be assumed that the patients are homozygous for an autosomal recessive gene. The parents would thus be heterozygous and mildly affected.
Another genetic model could be the presence of double dominant heterozygosity in both patients. Each parent would be heterozygous for an autosomal dominant gene for a different type of abnormal collagen at different loci, and their offspring would thus be heterozygotes for each one of these genes. Mutations at different loci, with alterations of different subunits of collagen, are potentially possible, even though they have not been demonstrated so far.
Until further knowledge is obtained on a specific molecular defect in Marfan syndrome, genetic counselling will be based on theoretical recurrence risk figures. Assuming that the two patients represent homozygosity for the autosomal dominant Marfan syndrome gene, the recurrence risks in each pregnancy would be 25 % and 50 % for homozygous and heterozygous Marfan syndrome, respectively. This work was supported in part by a grant from the Advancement of Mankind foundation (to DD).
